Skip to content
Other Driver Mutations: ROS-1, BRAF, MET and RET
Non Driver NSCLC: The Immunotherapy Strategy
Small Cell Lung Cancer: Targeting This Difficult Target
Novel Advances in T-Cell NHL Therapies
What Is New for DLBCL and & Hodgkin’s Disease?
Navigating Mantle Cell Lymphoma in the Era of Targeted Therapy
CLL: Therapeutic Advances in 2024
Targeted Therapy in Hema Malignancies (CD20, CD30, CD33, BCR/ABL, FLT3, IDH1/2)
De Novo Acute Myeloid Leukemia
CAR-T Cell Therapy in Lymphomas: 7-Years Later
Novel Therapeutic Strategies for MDS Based on Molecular Profile
Acquired Inhibitors in Cancer: State-of-the Art Management
Novel Advances in Myelofibrosis: Diagnosis-Risk Stratification-Therapy
Selecting the Best Frontline Therapy for Transplant Eligible Myeloma Patients
Sequencing Therapy in Relapsed/Refractory Myeloma Patients
Clinical Update: Cell and Gene Therapy, the Future of Medicine
The Art and the Science of Formulary Management | Acute to Ambulatory Strategies
Clinical Update: Biosimilars to Adalimumab
Minimizing Waste by Maximizing BUDs: Immediate Use Compounding for Biologics
Policy Update - Financial Survival: It’s not Easy Being Green!!
Clinical and Practice Considerations in the Management of Iron Deficiency Anemia
White Bagging & The Movement for Policy Development
Clinical Update: Malignant Hematology
